Headquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.
Iovance Biotherapeutics, IncIovance Biotherapeutics develops and manufactures personalized tumor-infiltrating lymphocyte (TIL) cell therapies for people with cancer. Its 136,000-square-foot Iovance Cell Therapy Center in Philadelphia makes TIL therapy using proprietary processes, including a 22-day Gen 2 process; the company also markets Amtagvi and Proleukin.PHILADELPHIA, PA
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
Rise Therapeutics, LLCRockville-based Rise Therapeutics develops oral immunotherapies that use synthetic biology to target dendritic cells and recalibrate immune responses in autoimmune disease and cancer. The clinical-stage company pairs its proprietary oral delivery platform with in-house clinical GMP manufacturing, taking candidates from discovery through human clinical validation. Its pipeline includes oral programs for ulcerative colitis, rheumatoid arthritis, and cancer.POTOMAC, MD
MesoblastFounded in 2004 by physician-scientist Silviu Itescu, Mesoblast develops and manufactures allogeneic, off-the-shelf cellular medicines for severe inflammatory and tissue-damage conditions. Its proprietary mesenchymal lineage cell platform supports Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, while the company advances additional therapies through operations in Australia, the United States and Singapore. Mesoblast’s manufacturing approach is designed for industrial-scale production of cryopreserved cell products without donor-recipient matching.NEW YORK, NY